Spackman Equities Group Inc. (TSXV: SQG) (the "Company" or "SEGI") has entered into an advisory agreement (the "Agreement") ...

Roche has received FDA approval for a label expansion of its PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which identifies patients with HR–positive, HER2-ultralow metastatic ...

The PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test is used with Roche’s fully automated BenchMark IHC/ISH slide-staining instrument.

The FDA makes furthering moves in SCLC, ovarian, and breast cancers, and the value of remote clinical pharmacists is explored in community oncology.

Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer ...

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate ...

FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.

ERBB2 status (formerly HER2 or HER2/neu), cause of death and survival (months). We used the cause of death to site recode variables in SEER 18 to extract patient status at the time of the last ...

Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer. All patients with breast cancer who may be candidates for antibody-drug ...

If breast cancer is diagnosed at an early stage, it has a higher chance of being cured. Therefore, it is important that you get tests done at regular intervals as it can help in early diagnosis of ...